Home / Companies / Bluefish Publ
Company family
Bluefish Publ: medicine shortages
As of 2 Nov 2026, 4 Bluefish Publ products have a reported shortage across 2 countries, covering 3 medicines.
Products short4rank #344 of 464
Medicines3active ingredients
Countries2/16
New in 90 days1+1 vs market pace
Typical duration23 monthsmedian so far
Manufacturing100%demand-driven 0%
Where
Which therapeutic classes
Why, compared with all companies
Manufacturing problemIncreased demandActive ingredient shortageDistribution or logisticsCommercial decision or withdrawalRegulatory or licensingOtherNot stated
Manufacturing problems point to the company's own supply chain; increased demand often follows a competitor's shortage or a demand shock.
When its current shortages began
Against its peers
Breadth vs depth
Further right: more products short. Higher: more different medicines affected.
Medicines short
| Medicine | Where this company is short | Products | Earliest start | Main reason | Short anywhere |
|---|---|---|---|---|---|
| Alendronic Acid and Colecalciferol | 2 | 2 Oct 2023 | Not stated | 5/16 | |
| Anagrelide | 1 | 27 Sep 2026 | Not stated | 3/16 | |
| Eletriptan | 1 | 1 Mar 2026 | Manufacturing problem | 7/16 |
Shortage data describes supply, not company finances. A shortage can mean lost sales for the supplier or extra demand for its competitors. Nothing here is investment advice; tickers are for identification only and may be out of date.